A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of two new drugs, cetuximab
(Erbitux) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and
neck cancer. Cetuximab has recently been approved by the FDA for head and neck cancer (that
is locally or regionally advanced) when used in combination with radiation therapy. Cetuximab
is also approved by the FDA for the treatment of colorectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI) University of Pittsburgh